[go: up one dir, main page]

BR9916069A - Sistema de expressão para fator viii - Google Patents

Sistema de expressão para fator viii

Info

Publication number
BR9916069A
BR9916069A BR9916069-2A BR9916069A BR9916069A BR 9916069 A BR9916069 A BR 9916069A BR 9916069 A BR9916069 A BR 9916069A BR 9916069 A BR9916069 A BR 9916069A
Authority
BR
Brazil
Prior art keywords
factor viii
protein
procoagulant activity
cells
expression system
Prior art date
Application number
BR9916069-2A
Other languages
English (en)
Other versions
BRPI9916069B8 (pt
BRPI9916069B1 (pt
Inventor
Myung-Sam Cho
Sham Yuen Chan
William Kelsey
Helena Yee
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR9916069A publication Critical patent/BR9916069A/pt
Publication of BRPI9916069B1 publication Critical patent/BRPI9916069B1/pt
Publication of BRPI9916069B8 publication Critical patent/BRPI9916069B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

Patente de Invenção: <B>"SISTEMA DE EXPRESSãO PARA FATOR VIII"<D>. Esta invenção descreve um processo de produção isento de proteínas para proteínas tendo atividade pró-coagulante de fator VIII. Geralmente, o processo inclui a derivação de clones de células humanas estáveis com alta produtividade para fator VIII deletado com domínio B, e (2) a adaptação de células para cultivo em um meio isento de proteínas derivadas de plasma. Mais especificamente, o processo inclui transfectar células humanas com um vetor, como na figura, compreendendo um marcador selecionável e uma seq³ência codificando a proteína tendo atividade pró-coagulante de fator VIII, selecionar células com um agente de seleção e isolar clones expressando altos níveis da proteína tendo atividade pró-coagulante de fator VIII.
BRPI9916069A 1998-12-10 1999-12-08 processo para produção e isolamento de proteína com atividade de fator viii, linhagem de célula humana híbrida com atividade de fator viii e linhagem de celula híbrida BRPI9916069B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/209,916 US6358703B1 (en) 1998-12-10 1998-12-10 Expression system for factor VIII
PCT/US1999/029169 WO2000034505A1 (en) 1998-12-10 1999-12-08 Expression system for factor viii

Publications (3)

Publication Number Publication Date
BR9916069A true BR9916069A (pt) 2001-09-04
BRPI9916069B1 BRPI9916069B1 (pt) 2016-08-02
BRPI9916069B8 BRPI9916069B8 (pt) 2021-05-25

Family

ID=22780858

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9916069A BRPI9916069B8 (pt) 1998-12-10 1999-12-08 processo para produção e isolamento de proteína com atividade de fator viii, linhagem de célula humana híbrida com atividade de fator viii e linhagem de celula híbrida

Country Status (26)

Country Link
US (10) US6358703B1 (pt)
EP (1) EP1137797B1 (pt)
JP (1) JP4240818B2 (pt)
KR (1) KR100616028B1 (pt)
AT (1) ATE412765T1 (pt)
AU (1) AU761801B2 (pt)
BG (1) BG65431B1 (pt)
BR (1) BRPI9916069B8 (pt)
CA (1) CA2354845C (pt)
CZ (1) CZ302330B6 (pt)
DE (1) DE69939839D1 (pt)
DK (1) DK1137797T3 (pt)
ES (1) ES2315026T3 (pt)
HU (1) HU228489B1 (pt)
IL (2) IL143353A0 (pt)
NO (1) NO329544B1 (pt)
NZ (1) NZ512234A (pt)
PL (1) PL200676B1 (pt)
PT (1) PT1137797E (pt)
RO (1) RO121604B1 (pt)
RU (1) RU2249041C2 (pt)
SI (1) SI20644B (pt)
SK (1) SK286945B6 (pt)
TR (1) TR200101592T2 (pt)
UA (1) UA77383C2 (pt)
WO (1) WO2000034505A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
US6180108B1 (en) * 1998-12-10 2001-01-30 Bayer Corporation Vectors having terminal repeat sequence of Epstein-Barr virus
CZ303929B6 (cs) * 2000-03-22 2013-07-03 Octapharma Biopharmaceuticals Gmbh Mutein faktoru VIII, odpovídající DNA sekvence, vektor a hostitelská bunka, farmaceutická kompozice, zpusob produkce muteinu a imortalizovaná lidská bunecná linie
US7205278B2 (en) * 2001-06-14 2007-04-17 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
HUE058897T2 (hu) 2003-02-26 2022-09-28 Nektar Therapeutics Polimer VIII-as faktor egység konjugátumok
JP4644663B2 (ja) * 2003-06-03 2011-03-02 セル ジェネシス インコーポレイテッド ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
EP1812557A4 (en) * 2004-10-29 2009-11-04 Centocor Ortho Biotech Inc COMPOSITIONS OF CHEMICALLY DEFINED MEDIA
ES2821832T3 (es) 2004-11-12 2021-04-27 Bayer Healthcare Llc Modificación de FVIII dirigida al sitio
CN106589132B (zh) 2005-12-20 2022-03-29 布里斯托尔-迈尔斯斯奎布公司 组合物和用于生产组合物的方法
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
US9359629B2 (en) * 2007-12-27 2016-06-07 Baxalta Incorporated Cell culture processes
KR101005967B1 (ko) * 2008-04-12 2011-01-05 (주)셀트리온 우수한 재조합 단백질을 생산하기 위한 인간 숙주 세포
CN102137935A (zh) * 2008-06-25 2011-07-27 拜耳医药保健有限公司 具有降低的免疫原性的因子viii突变蛋白
US9120873B2 (en) 2008-08-21 2015-09-01 Octapharma Ag Recombinantly produced human factor VIII and IX
CN107049964B (zh) * 2008-09-03 2020-06-02 奥克塔法马股份有限公司 重组制备的因子viii的新型保护组合物
CN108530543B (zh) 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
CN102427823A (zh) * 2009-03-24 2012-04-25 拜耳医药保健有限公司 因子viii变体及使用方法
US9062299B2 (en) 2009-08-24 2015-06-23 Amunix Operating Inc. Coagulation factor IX compositions and methods of making and using same
US20110150843A1 (en) * 2009-10-30 2011-06-23 National Institute Of Immunology Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells
US20130017997A1 (en) * 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
WO2012156356A1 (en) 2011-05-13 2012-11-22 Octapharma Ag A method of increasing the productivity of eucaryotic cells in the production of recombinant fviii
CN109111526A (zh) 2012-01-12 2019-01-01 比奥贝拉蒂治疗公司 嵌合因子viii多肽及其用途
EP3564260B1 (en) * 2012-02-15 2022-10-19 Bioverativ Therapeutics Inc. Factor viii compositions and methods of making and using same
BR112014019901A8 (pt) 2012-02-15 2018-01-02 Biogen Idec Inc Proteínas de fator viii recombinante
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
HUE059820T2 (hu) 2014-01-10 2022-12-28 Bioverativ Therapeutics Inc VIII-as faktor kimérafehérjéi és azok alkalmazása
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
EP4343774A3 (en) 2016-04-15 2024-06-05 Takeda Pharmaceutical Company Limited Method and apparatus for providing a pharmacokinetic drug dosing regiment
WO2018017923A1 (en) 2016-07-22 2018-01-25 Nektar Therapeutics Conjugates of a factor viii moiety having an oxime-containing linkage
EP3548066A1 (en) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
WO2019055717A1 (en) * 2017-09-13 2019-03-21 Evolve Biosystems, Inc. OLIGOSACCHARIDE COMPOSITIONS AND THEIR USE DURING THE TRANSIENT PHASES OF INTESTINAL MICROBIOMA OF A MAMMALIAN
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
HRP20250709T1 (hr) 2018-05-18 2025-08-15 Bioverativ Therapeutics Inc. Postupci liječenja hemofilije a
JP7672334B2 (ja) * 2018-10-23 2025-05-07 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 第ｖｉｉｉ因子機能を調節するための組成物および方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045849B2 (ja) 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
KR890002004B1 (ko) * 1984-01-11 1989-06-07 가부시끼 가이샤 도오시바 지폐류 판별장치
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
US4868112A (en) 1985-04-12 1989-09-19 Genetics Institute, Inc. Novel procoagulant proteins
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
DE3769872D1 (de) * 1986-07-11 1991-06-13 Miles Inc Herstellung von rekombinantem protein.
AU613316B2 (en) 1986-09-12 1991-08-01 Genentech Inc. Improved recombinant expression
IE69026B1 (en) * 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DK0502976T3 (da) * 1989-12-01 1996-11-11 Pharming Bv Produktion af rekombinante polypeptider ved bovine arter og transgene fremgangsmåder
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
DE69433925T2 (de) * 1993-06-10 2005-07-28 Bayer Corp. Vektoren und Zelllinien von Säugetieren mit erhöhter Produktivität
US5952198A (en) * 1995-05-04 1999-09-14 Bayer Corporation Production of recombinant Factor VIII in the presence of liposome-like substances of mixed composition
DE19517194A1 (de) * 1995-05-11 1996-11-14 Giesecke & Devrient Gmbh Vorrichtung und Verfahren zur Prüfung von Blattgut, wie z.B. Banknoten oder Wertpapiere
MX9504215A (es) 1995-10-05 1997-04-30 Inst Politecnico Nacional Procedimiento mejorado para la purificacion de oligopeptidos con pesos moleculares de 1000 a 10,000 daltones, a partir de estractos leucocitos y su presentacion farmaceutica.
US5922959A (en) * 1996-10-15 1999-07-13 Currency Systems International Methods of measuring currency limpness
US5923413A (en) * 1996-11-15 1999-07-13 Interbold Universal bank note denominator and validator
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
JP2002517180A (ja) * 1997-12-05 2002-06-18 ジ・イミユーン・リスポンス・コーポレーシヨン 増大された発現を示す新規ベクターおよび遺伝子
US6040584A (en) * 1998-05-22 2000-03-21 Mti Corporation Method and for system for detecting damaged bills
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6136599A (en) * 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
US6180108B1 (en) 1998-12-10 2001-01-30 Bayer Corporation Vectors having terminal repeat sequence of Epstein-Barr virus

Also Published As

Publication number Publication date
BG65431B1 (bg) 2008-07-31
AU761801B2 (en) 2003-06-12
PT1137797E (pt) 2008-12-26
UA77383C2 (uk) 2006-12-15
CZ20012024A3 (cs) 2001-10-17
HU228489B1 (en) 2013-03-28
EP1137797A1 (en) 2001-10-04
JP4240818B2 (ja) 2009-03-18
SK286945B6 (sk) 2009-08-06
SK7922001A3 (en) 2002-01-07
US20110144025A1 (en) 2011-06-16
AU2170100A (en) 2000-06-26
JP2002531137A (ja) 2002-09-24
IL143353A (en) 2010-12-30
BG105567A (en) 2002-03-29
EP1137797B1 (en) 2008-10-29
NO20012718L (no) 2001-06-01
US20020102730A1 (en) 2002-08-01
US20170267745A1 (en) 2017-09-21
KR20020013481A (ko) 2002-02-20
KR100616028B1 (ko) 2006-08-28
WO2000034505A1 (en) 2000-06-15
PL349284A1 (en) 2002-07-15
US20130143818A1 (en) 2013-06-06
CA2354845C (en) 2008-08-12
PL200676B1 (pl) 2009-01-30
CZ302330B6 (cs) 2011-03-16
US9650431B2 (en) 2017-05-16
RO121604B1 (ro) 2007-12-28
HUP0200558A2 (en) 2002-06-28
DK1137797T3 (da) 2009-02-23
US8945869B2 (en) 2015-02-03
HUP0200558A3 (en) 2004-11-29
US20020115152A1 (en) 2002-08-22
ES2315026T3 (es) 2009-03-16
RU2249041C2 (ru) 2005-03-27
SI20644B (sl) 2009-04-30
US9249209B2 (en) 2016-02-02
EP1137797A4 (en) 2005-06-22
NO20012718D0 (no) 2001-06-01
ATE412765T1 (de) 2008-11-15
IL143353A0 (en) 2002-04-21
BRPI9916069B8 (pt) 2021-05-25
CA2354845A1 (en) 2000-06-15
US20030077752A1 (en) 2003-04-24
DE69939839D1 (de) 2008-12-11
US8207117B2 (en) 2012-06-26
SI20644A (sl) 2002-02-28
US6358703B1 (en) 2002-03-19
US20090036358A1 (en) 2009-02-05
BRPI9916069B1 (pt) 2016-08-02
US20130267468A1 (en) 2013-10-10
NO329544B1 (no) 2010-11-08
US20160115219A1 (en) 2016-04-28
NZ512234A (en) 2002-12-20
US7459525B2 (en) 2008-12-02
TR200101592T2 (tr) 2001-11-21

Similar Documents

Publication Publication Date Title
BR9916069A (pt) Sistema de expressão para fator viii
Johnson et al. Nuclear accumulation of epidermal growth factor in cultured rat pituitary cells
AR056723A2 (es) Polipeptido purificado metodo para producirlo , metodo para identificarlo y/ o aislarlo composicion farmaceutica que lo comprende, secuencia de acidos nucleicos aislada que codifica dicho polipeptido, vector que contiene a dicha secuencia celula huesped transfectada por dicho vector, sonda nucleotid
BR9915604A (pt) Peptìdios inibidores de tgfbeta1
GT199700091A (es) Celdillas de alta resistencia para el desarrollo de virus.
DE69933550D1 (de) Modifizierte adenoviren welche ein faserersatzprotein enthalten
BR9406232A (pt) Novo agente para controle da atividade celular
DK0733103T3 (da) Fremstilling af höje titre af rekombinante AAV vektorer
AU1750297A (en) Humanized green fluorescent protein genes and methods
DK0851868T3 (da) Höjniveau-ekspression af proteiner
US6114148C1 (en) High level expression of proteins
AU2002257420A1 (en) A system for inducible expression in eukaryotic cells
AU3752795A (en) Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
DE69128893D1 (de) Genetische veränderung von endothelzellen
BR9306289A (pt) Processo para produzir lactoferrina recombinante biologicamente ativa lactoferrina plasmídeo adotado para expressão em uma célula eucariótica célula eucariótica processo para produzir lactoferrina vetor de expressão recombinante e produto de proteína
ATE288480T1 (de) Chondrogene in vitro induktion von menschlichen mensenchymalen stammzellen
AR020048A1 (es) Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero.
EP0657534A4 (en) ANTIALLERGIC AGING.
ES2167326T3 (es) N-acetilglucosaminil-transferasa, gen que la codifica, vectores y huespedes transformados correspondientes y procedimientos para su produccion.
NO995928L (no) Alfa-1-antitrypsin-preparater samt fremgangsmåte ved fremstilling derav
NO974035L (no) En ny vekstfaktor og en genetisk sekvens som koder for denne
PT1025245E (pt) Criacao rapida de linhas celulares estaveis de mamifero produzindo elevados iiveis de proteinas recombinantes
Hitt et al. De novo and maintenance DNA methylation by a mouse plasmacytoma cell DNA methyltransferase.
DE69033756D1 (de) Gene, die für MACIF Proteine kodieren, Expressionsvektoren mit diesem Genen, und Transformantenzellen mit diesem Proteinen
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/08/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/12/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 08/12/2019